首頁 > 市場調查報告書 > 製藥

DDS

市場調查報告書

商品編碼

1394963

長效給藥技術和服務市場：全球和區域分析（2023-2033）

Long-Acting Drug Delivery Technologies and Services Market: A Global and Regional Analysis, 2023-2033

出版日期: 2023年12月11日 | 出版商:

BIS Research | 英文 92 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

截至2022年，全球長效給藥技術及服務市場規模達114.1億美元。

預計到2033年，該市場將達到 368.2 億美元，2023-2033年預測期間年複合成長率為 11.31%。市場的軌跡顯示對醫藥保健產生了變革性的影響，擅長應對監管複雜性和擁抱技術創新的公司有望取得更大的成功。

主要市場統計資料
預測期	2023-2033
2023年評估值	126.1億美元
2033年預測	368.2億美元
年複合成長率	11.31%

全球長效給藥技術和服務市場正處於成長階段。這一階段的特徵是需求和採用量顯著增加，反映出人們對長效藥物輸送解決方案的認知和接受度不斷提高。慢性病盛行率上升，技術進步以及轉向以患者為中心的方法等主要促進因素推動市場向前發展。創新配方和輸送系統獲得關注，吸引投資並促進製藥和科技部門之間的合作。儘管監管複雜性和成本等挑戰仍然存在，但整體軌跡顯示市場動態擴張。

市場擴張機會，特別是在新興地區和治療應用領域，進一步體現了成長階段。隨著產業的不斷發展，有效克服挑戰並抓住機會的公司將處於有利位置，為長效給藥技術和服務市場的成熟和永續性做出貢獻。

長效給藥技術和服務對該行業產生重大影響，影響製藥和醫療保健行業的許多方面。其中一項重大影響體現在患者的治療結果和醫囑遵從性。長效給藥系統的採用有助於提高病患的醫囑遵從性。這是因為這些技術通常需要更少的給藥，減少了給藥劑量的機會並提高了整體治療效果。這種對患者治療結果的正面影響不僅可以提高醫療保健品質，而且有可能降低與治療不足和次優治療相關的醫療保健成本。

此外，這個市場也掀起醫藥產業的創新與合作浪潮。公司投資研發，以創造新的配方和給藥方法，創造一個優先考慮效率和以患者為中心的解決方案的競爭形勢。製藥科學家、工程師和臨床醫生之間跨學科合作的出現加速超越傳統藥物傳輸機制的尖端最尖端科技的發展。

本報告研究了全球長效藥物輸送技術和服務市場，提供了市場概述、技術趨勢、劑型、分子類型、使用的材料、配銷通路、區域，並提供了進入市場的公司概況， ETC。

Market Overview

As of 2022, the global long-acting drug delivery technologies and services market held a value of $11.41 billion. The market is expected to grow at a CAGR of 11.31% during the forecast period 2023-2033 and attain a value of $36.82 billion by 2033. The market's trajectory suggests a transformative impact on pharmaceutical care, with companies adept at addressing regulatory complexities and embracing technological innovations poised for significant success.

KEY MARKET STATISTICS
Forecast Period	2023 - 2033
2023 Evaluation	$12.61 Billion
2033 Forecast	$36.82 Billion
CAGR	11.31%

Market Lifecycle Stage

The global long-acting drug delivery technologies and services market is in a growing phase. Characterized by a significant increase in demand and adoption, this stage reflects the rising recognition and acceptance of long-acting drug delivery solutions. Key drivers, including the growing prevalence of chronic diseases, technological advancements, and a shift toward patient-centric approaches, are propelling the market forward. Innovative formulations and delivery systems are gaining traction, attracting investments and fostering collaborations across pharmaceutical and technology sectors. While challenges such as regulatory complexities and cost considerations persist, the overall trajectory suggests a dynamic and expanding market.

Opportunities for market expansion, particularly in emerging regions and therapeutic applications, further underscore the growth stage characteristics. As the industry continues to evolve, companies that effectively navigate challenges and capitalize on opportunities are well-positioned to contribute to the maturity and sustainability of the long-acting drug delivery technologies and services market.

Industry Impact

The industry impact of long-acting drug delivery technologies and services is profound, influencing various facets of the pharmaceutical and healthcare sectors. One significant effect is observed in patient outcomes and adherence. The adoption of long-acting drug delivery systems contributes to improved patient adherence, as these technologies often require less frequent dosing, reducing the likelihood of missed doses and enhancing overall treatment efficacy. This positive impact on patient outcomes not only enhances the quality of healthcare but also potentially reduces healthcare costs associated with untreated or sub-optimally treated conditions.

Furthermore, the market has spurred a wave of innovation and collaboration within the pharmaceutical industry. Companies are investing in research and development to create novel drug formulations and delivery methods, fostering a competitive landscape that prioritizes efficiency and patient-centric solutions. The emergence of interdisciplinary collaborations between pharmaceutical scientists, engineers, and clinicians is accelerating the development of cutting-edge technologies that go beyond traditional drug delivery mechanisms.

Market Segmentation:

Segmentation 1: by Technique

Long-Acting Injectables
Long-Acting Hydrogels
Long-Acting Implants
Long-Acting Microneedles
Nanocrystal Suspensions

Long-Acting Injectables to Dominate the Global Long-Acting Drug Delivery Technologies and Services Market (by Technique)

The long-acting injectables segment dominated the global long-acting drug delivery technologies and services market (by technique) in FY2022. The increasing preference for injectable formulations stems from their ability to provide sustained drug release over an extended period, offering advantages such as reduced dosing frequency and enhanced patient compliance. This dominance is particularly evident in therapeutic areas where a consistent and prolonged therapeutic effect is crucial, such as chronic diseases and certain mental health conditions.

Segmentation 2: by Dosage Form

Injectables
Implantable
Topical/Transdermal
Vaginal
Other Dosage Forms

Injectables to Dominate the Global Long-Acting Drug Delivery Technologies and Services Market (by Dosage Form)

The injectables segment dominated the global long-acting drug delivery technologies and services market (by dosage forms) in FY2022. Injectables are characterized by sustained and controlled drug release through injection, are gaining prominence across various therapeutic areas, thereby reshaping the landscape of long-acting drug delivery solutions.

Segmentation 3: by Type of Molecule Delivered

Small Molecules
Biologics
Other Molecules

Small Molecules to Dominate the Global Long-Acting Drug Delivery Technologies and Services Market (by Type of Molecule Delivered)

The global long-acting drug delivery technologies and services market (by type of molecule delivered) was dominated by the small molecules segment in FY2022. Small molecules, characterized by their molecular size and structure, are poised to take center stage in this market, driven by their versatility, widespread therapeutic applications, and advancements in drug formulation technologies.

Segmentation 4: by Material Used

Polymer Based
Non-Polymer Based

Polymer Based to Dominate the Global Long-Acting Drug Delivery Technologies and Services Market (by Material Used)

The global long-acting drug delivery technologies and services market (by material used) was dominated by the polymer based segment in FY2022. This trend reflects a strategic shift toward the utilization of polymers for the development of long-acting drug delivery systems, driven by their versatility, biocompatibility, and ability to modulate drug release profiles effectively.

Segmentation 5: by End User

Biopharmaceutical and Life science Companies
Research and Academics

Biopharmaceutical and Life science Companies to Continue its Dominance in the Global Long-Acting Drug Delivery Technologies and Services Market (by End User)

The Biopharmaceutical and Life science Companies segment accounted for the largest share of the global long-acting drug delivery technologies and services market (by End User) in FY2022. Biopharmaceutical and life science companies are poised to sustain their dominant role in the global long-acting drug delivery technologies and services market as primary end users. This enduring dominance can be attributed to several key factors that highlight the pivotal role these companies play in driving innovation, research, and development within the pharmaceutical industry.

Segmentation 6: by Region

North America
Europe
Asia-Pacific
Rest-of-the-World

China dominated the Asia-Pacific market in 2022 with a share of 36.40%. Moreover, Asia-Pacific is expected to register the highest CAGR of 12.70% during the forecast period 2023-2033. The long-acting drug delivery technologies and services market in the Asia-Pacific (APAC) region is witnessing significant growth, marked by increasing demand, technological advancements, and a shifting healthcare landscape. This growth reflects a convergence of factors contributing to the adoption and expansion of long-acting drug delivery solutions across diverse therapeutic areas.

Recent Developments in the Global Long-Acting Drug Delivery Technologies and Services Market

In August 2023, AMW GmbH opened new European and international markets with its goserelin implant's first Notified Body Opinion (NBO) report.

In November, AMW GmbH and AdhexPharma announced a strategic partnership for transdermal delivery systems.

In February 2023, Innocore Pharmaceuticals, a Dutch pharmaceutical company specializing in the development of polymer-based long-acting injectables, secured funding from the European Regional Development Fund to develop a biodegradable polymer-based microneedle array patch for effective and simplified vaccine administration.

In March 2023, DelSiTech was granted to develop controlled and sustained-release injectables for the prophylactic HIV vaccine.

Demand - Drivers, Restraints, and Opportunities

Market Drivers:

Growing adoption of sustained release drugs and technologies: The increasing adoption of sustained release drugs and related technologies is a key driver for the growth of the long-acting drug delivery technologies and services market. This trend reflects a shift toward developing pharmaceutical products that offer prolonged therapeutic effects, reducing the frequency of drug administration and improving patient compliance.

Market Restraints:

Limitations of long-acting drug delivery technologies: The global long-acting drug delivery technologies and services market faces hindrances due to several limitations associated with these technologies. These challenges impact the widespread adoption and growth of the market. Some key limitations include the potential for a delayed onset of action, restricting their use in situations requiring rapid therapeutic effects.

Market Opportunities:

Introduction of biologics and biosimilars compatibility in technologies: The further evolution of the development of biologics and biosimilars compatible long-acting drug delivery technologies acts as an opportunity for the market. These technologies are expected to open the potential of treating different therapeutic areas that are biologic and biosimilar dependent via long-acting drug delivery systems.

How can this report add value to an organization?

Workflow/Innovation Strategy: The long-acting drug delivery technologies and services market (by technique) has been segmented into detailed segments of techniques, including different types of techniques such as long-acting injectables, long-acting hydrogels, long-acting implants, long-acting microneedles, and nanocrystal suspensions. Moreover, the study provides the reader with a detailed understanding of the different types of molecules delivered and the material used.

Growth/Marketing Strategy: The long-acting drug delivery technologies and services market encompasses a range of products and services designed to extend the duration of drug action. These technologies aim to improve patient compliance, reduce the frequency of drug administration, and enhance the overall efficacy of therapeutic interventions. This market includes various drug delivery systems and services that provide sustained release, controlled release, or targeted drug delivery over an extended period.

Competitive Strategy: Key players in the global long-acting drug delivery technologies and services market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the global long-acting drug delivery technologies and services market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

The base year considered for the calculation of the market size is 2022. The historical year analysis has been done from FY2020 to FY2021, and the market size has been calculated for FY2022 and projected for the period 2023-2033.
The geographical distribution of the market revenue is estimated to be the same as the company's net revenue distribution. All the numbers are adjusted to two digits after decimals for report presentation reasons. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. CAGR is calculated from 2023 to 2033.
The market has been mapped based on different types of products available in the market and based on several indications. All the key manufacturing companies that have a significant number of offerings to the long-acting drug delivery technologies and services market have been considered and profiled in the report.
In the study, the primary respondent's verification has been considered to finalize the estimated market for the long-acting drug delivery technologies and services market.
The latest annual reports of each market player have been taken into consideration for market revenue calculation.
Market strategies and developments of key players have been considered for the calculation of sub-segment split.
The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year. The currency conversion rate has been taken from the historical exchange rate of the Oanda website or from the annual reports of the respective company if stated.

Primary Research

The key data points taken from the primary sources include:

Validation and triangulation of all the numbers and graphs
Validation of the report's segmentation and key qualitative findings
Understanding of the numbers of the various markets for market type
Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

National Center for Biotechnology Information (NCBI), PubMed, Science Direct, World Bank Group, Organisation for Economic Co-operation and Development (OECD), Centers for Disease Control and Prevention (CDC), Global Burden Disease (GBD), and World Health Organization (WHO)
Annual reports, SEC filings, and investor presentations of the leading market players
Company websites and detailed study of their portfolio
Gold standard magazines, journals, whitepapers, press releases, and news articles
Databases

The key data points taken from the secondary sources include:

Segmentations, split-ups, and percentage shares
Data for market value
Key industry trends of the top players in the market
Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The long-acting drug delivery technologies and services competition seeks to catalyze innovation in the field of pharmaceuticals by encouraging the development of novel, efficient, and patient-friendly drug delivery systems. This competition aims to address the challenges associated with traditional drug administration methods, such as frequent dosing and patient adherence, by promoting the exploration and implementation of long-acting drug delivery technologies.

The global market for long-acting drug delivery technologies and services is experiencing substantial growth, driven by the escalating prevalence of chronic diseases and technological advancements in drug formulation and delivery systems. With a focus on patient-centric solutions and personalized medicine, these technologies offer a more convenient and efficient means of drug administration, improving patient adherence and treatment outcomes.

Some of the prominent companies in this market are:

Adare Pharma Solutions
Alkermes
AMW Gmb
Camurus AB
Corium, LLC.
Creative Biolabs

Delpor, Inc.
Durect Corporation
Hanmi Pharm Co Ltd.
Heron Therapeutics, Inc.
Integral BioSystems
NANEXA AB

Companies that are not a part of the aforementioned pool have been well-represented across different sections of the report (wherever applicable).

1. Scope and Definition

1.1. Market Definition
1.2. Key Questions Answered in the Report
1.3. Analyst and Forecast Note

2. Markets: Industry Outlook

2.1. Current and Future State of Long-Acting Drug Delivery Technologies and Services in Industries
2.2. Key Benefits of Long-Acting Drug Delivery
2.3. Market Footprint and Growth Potential, $Million, 2022-2033
2.4. Market Dynamics Overview
2.5. Market Drivers
2.6. Market Restraints
2.7. Market Opportunities

3. Global Long-Acting Drug Delivery Technologies and Services Market (by Technique), 2022-2033

3.1. Technique Summary
3.2. Long-Acting Injectables
3.3. Long-Acting Hydrogels
3.4. Long-Acting Implants
3.5. Long-Acting Microneedles
3.6. Nanocrystal Suspensions

4. Global Long-Acting Drug Delivery Technologies and Services Market (by Dosage Forms), 2022-2033

4.1. Dosage Forms Summary
4.2. Long-acting Injectables
4.3. Long-acting Implantable
4.4. Topical / Transdermal
4.5. Vaginal
4.6. Other Dosage Forms

5. Global Long-Acting Drug Delivery Technologies and Services Market (by Type of Molecule Delivered), 2022-2033

5.1. Type of Molecule Delivered Summary
5.2. Small Molecules
5.3. Biologics
5.4. Other Molecules (Peptides)

6. Global Long-Acting Drug Delivery Technologies and Services Market (by Material Used), 2022-2033

6.1. Material-Used Summary
6.2. Polymer based
6.3. Non-polymer based

7. Global Long-Acting Drug Delivery Market (by Distribution Channels), 2022-2033

7.1. Distribution Channels Summary
7.2. Hospitals and Retail Pharmacies
7.3. Research and Academics
7.4. Others

8. Global Long-Acting Drug Delivery Technologies and Services Market, by Region, 2022-2033

8.1. Regional Summary
8.2. Drivers and Restraints
8.3. North America
- 8.3.1. U.S.
- 8.3.2. Canada
8.4. Europe
- 8.4.1. Germany
- 8.4.2. U.K.
- 8.4.3. France
- 8.4.4. Italy
- 8.4.5. Spain
- 8.4.6. Rest-of-Europe
8.5. Asia Pacific
- 8.5.1. China
- 8.5.2. Japan
- 8.5.3. India
- 8.5.4. South Korea
- 8.5.5. Australia
- 8.5.6. Rest-of-Asia-Pacific
8.6. Rest-of-the-World